Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dalton Pharma Services has entered into a manufacturing agreement for LE-Poly ICLC developed by Defence Research and Development Canada (DRDC).
Subscribe to our email newsletter
LE-Poly ICLC is an antiviral agent proven to be effective in animal studies against avian influenza virus, ebola and alphavirus infections.
Under a sub-contract from Oncovir, Dalton established and scaled up a cGMP manufacturing process that will facilitate production of LE-Poly ICLC for future clinical trials.
Dalton president and CEO Peter Pekos said the process by which LE-Poly ICLC is manufactured is considered by regulatory bodies to be an integral part of the observed biological activity.
"By being involved in the fundamental stage of manufacturing development, we expect the eventual manufacture of LE-Poly ICLC on a commercial scale will take place here in Canada at Dalton," Pekos added.
Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries.